Please read this leaflet carefully before you start to take your medicine. Keep this leaflet. You may need to read it again. If you have further questions, please ask your doctor or your pharmacist. This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them even if their symptoms are the same as yours. If any of the side effects get serious, or if you notice any side effects not listed in the leaflet, please tell your doctor or pharmacist.
Prophylaxis of endocarditis: Amoxil may be used for the prevention of bacteraemia, associated with procedures such as dental extraction, in patients at risk of developing bacterial endocarditis. Consideration should be given to official local guidance (e.g. national requirements) on the appropriate use of antibacterial agents. “Susceptibility of the causative organisms to the treatment should be tested (if possible), although the therapy may be initiated before the results are available.
Before initiating therapy with amoxil, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins.
Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of hypersensitivity to beta-lactam antibiotics. Erythematous (morbilliform) rashes have been associated with glandular fever in patients receiving amoxil. Prolonged use may also occasionally result in overgrowth of non-susceptible organisms.
In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxil, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxil crystalluria. In patients with renal impairment, the rate of excretion of amoxil will be reduced depending on the degree of impairment and it may be necessary to reduce the total daily unit amoxil dosage accordingly.
Abnormal prolongation of prothrombin time (increased INR) has been reported rarely in patients receiving amoxil and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.